Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT03445949

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03445949
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03445949. Randomized; no masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2025-06-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure
Acronym
SAFE-LAAC
Intervention (Drug)
short postimplantation dual antiplatelet therapy
Intervention (Drug)
extended postimplantation dual antiplatelet therapy
Intervention (Drug)
long-term treatment with a single antiplatelet agent
Intervention (Drug)
6 months treatment with a single antiplatelet agent
Lead sponsor
National Institute of Cardiology, Warsaw, Poland (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)

Record details

Record id
cardio:ct-nct03445949
Content hash
6261fa35dc7b02bfa59557182fd42191d615fc6dd743bf4a83d53cceff4f0a92